Back to Search
KAREN SAYLOR, M.D.
M.D.
Internal Medicine Physician
NPI: 1881760569IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
134107(KY)
Pediatrics Physician
Pediatrics
Code: 208000000X
045553(KY)
Education
UNIVERSITY OF KENTUCKY COLLEGE OF MEDICINE
Class of 1986
Research & Publications (20)
Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
PMID 19142107·J Clin Psychopharmacol·2009
4-observational
Emotional expression in children treated with ADHD medication: development of a new measure.
PMID 18192622·J Atten Disord·2008
4-observational
High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses.
PMID 17712236·J Am Acad Child Adolesc Psychiatry·2007
2-rct
Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment.
PMID 17979588·J Child Adolesc Psychopharmacol·2007
8-other
Emotional expression during attention-deficit/hyperactivity disorders treatment: initial assessment of treatment effects.
PMID 17343553·J Child Adolesc Psychopharmacol·2007
4-observational
Protecting our gifts and securing our future: Eliminating poverty among First Nations children.
PMID 19030441·Paediatr Child Health·2007
8-other
The Life Participation Scale for Attention-Deficit/Hyperactivity Disorder--Child Version: psychometric properties of an adaptive change instrument.
PMID 18315454·J Child Adolesc Psychopharmacol·2007
4-observational
The chloride intracellular channel protein CLIC5 is expressed at high levels in hair cell stereocilia and is essential for normal inner ear function.
PMID 17021174·J Neurosci·2006
7-preclinical
Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
PMID 17110824·J Clin Psychopharmacol·2006
4-observational
Many hands, one dream: Healthy Aboriginal children and young people.
PMID 19668679·Paediatr Child Health·2005
8-other
The effects of the going places program on early adolescent substance use and antisocial behavior.
PMID 16091854·Prev Sci·2005
2-rct
Impact analysis and mediation of outcomes: the Going Places program.
PMID 15749968·Health Educ Behav·2005
3-trial
Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
PMID 15231966·Pediatrics·2004
3-trial
A low-iron-available, polyphenol-enriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy.
PMID 12716753·Diabetes·2003
3-trial
Adaptive changes related to medication treatment of ADHD: listening to parents of children in clinical trials of a novel nonstimulant medication.
PMID 12562058·J Clin Psychiatry·2002
6-review
Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.
PMID 12411225·Am J Psychiatry·2002
3-trial
Effect of iron depletion on cardiovascular risk factors: studies in carbohydrate-intolerant patients.
PMID 12079862·Ann N Y Acad Sci·2002
8-other
Peer and parent influences on smoking and drinking among early adolescents.
PMID 11213145·Health Educ Behav·2001
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 140 NEWCOMB AVE
MOUNT VERNON, KY 40456 - Phone
- (606) 256-5176
Quick Facts
- NPI
- 1881760569
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 40
- Publications
- 20
Are you this provider?
Claim Your Profile